BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

305 related articles for article (PubMed ID: 24465570)

  • 1. Immunogenicity, impact on carriage and reactogenicity of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine in Kenyan children aged 1-4 years: a randomized controlled trial.
    Hammitt LL; Ojal J; Bashraheil M; Morpeth SC; Karani A; Habib A; Borys D; Goldblatt D; Scott JA
    PLoS One; 2014; 9(1):e85459. PubMed ID: 24465570
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) coadministered with DTPw-HBV/Hib and poliovirus vaccines: assessment of immunogenicity.
    Bermal N; Szenborn L; Chrobot A; Alberto E; Lommel P; Gatchalian S; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S89-96. PubMed ID: 19325451
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
    Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
    Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
    Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity, reactogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Mexican infants.
    Ruiz-Palacios GM; Guerrero ML; Hernández-Delgado L; Lavalle-Villalobos A; Casas-Muñoz A; Cervantes-Apolinar Y; Moreira M; Schuerman L
    Hum Vaccin; 2011 Nov; 7(11):1137-45. PubMed ID: 22048109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity, safety and reactogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian Infants: a randomised trial.
    Odusanya OO; Kuyinu YA; Kehinde OA; Francois N; Yarzabal JP; Moreira M; Borys D; Schuerman L
    Niger Postgrad Med J; 2013 Dec; 20(4):272-81. PubMed ID: 24633268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) compared to the licensed 7vCRM vaccine.
    Vesikari T; Wysocki J; Chevallier B; Karvonen A; Czajka H; Arsène JP; Lommel P; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S66-76. PubMed ID: 19325449
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial.
    Dicko A; Odusanya OO; Diallo AI; Santara G; Barry A; Dolo A; Diallo A; Kuyinu YA; Kehinde OA; François N; Borys D; Yarzabal JP; Moreira M; Schuerman L
    BMC Public Health; 2011 Nov; 11():882. PubMed ID: 22112189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
    Tregnaghi MW; Sáez-Llorens X; López P; Abate H; Smith E; Pósleman A; Calvo A; Wong D; Cortes-Barbosa C; Ceballos A; Tregnaghi M; Sierra A; Rodriguez M; Troitiño M; Carabajal C; Falaschi A; Leandro A; Castrejón MM; Lepetic A; Lommel P; Hausdorff WP; Borys D; Ruiz Guiñazú J; Ortega-Barría E; Yarzábal JP; Schuerman L;
    PLoS Med; 2014 Jun; 11(6):e1001657. PubMed ID: 24892763
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial.
    van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA
    Pediatr Infect Dis J; 2011 Sep; 30(9):e170-8. PubMed ID: 21487327
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of routinely used childhood vaccines when coadministered with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV).
    Knuf M; Szenborn L; Moro M; Petit C; Bermal N; Bernard L; Dieussaert I; Schuerman L
    Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S97-S108. PubMed ID: 19325452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
    Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
    Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study.
    Sirima SB; Tiono A; Gansané Z; Siribié M; Zongo A; Ouédraogo A; François N; Strezova A; Dobbelaere K; Borys D
    Pediatr Infect Dis J; 2017 May; 36(5):e136-e150. PubMed ID: 28403055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 10-valent pneumococcal non-typeable Haemophilus influenzae protein-D conjugate vaccine (PHiD-CV) induces memory B cell responses in healthy Kenyan toddlers.
    Muema DM; Nduati EW; Uyoga M; Bashraheil M; Scott JA; Hammitt LL; Urban BC
    Clin Exp Immunol; 2015 Aug; 181(2):297-305. PubMed ID: 25845628
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Taiwan.
    Lin TY; Lu CY; Chang LY; Chiu CH; Huang YC; Bock HL; Tang H; François N; Moreira M; Schuerman L; Huang LM
    J Formos Med Assoc; 2012 Sep; 111(9):495-503. PubMed ID: 23021506
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A randomised trial to evaluate the immunogenicity, reactogenicity, and safety of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Singapore and Malaysia.
    Lim FS; Koh MT; Tan KK; Chan PC; Chong CY; Shung Yehudi YW; Teoh YL; Shafi F; Hezareh M; Swinnen K; Borys D
    BMC Infect Dis; 2014 Oct; 14():530. PubMed ID: 25278086
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
    Lalwani S; Chatterjee S; Chhatwal J; Verghese VP; Mehta S; Shafi F; Borys D; Moreira M; Schuerman L
    Hum Vaccin Immunother; 2012 May; 8(5):612-22. PubMed ID: 22634448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
    Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
    Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children.
    Lagos RE; Muñoz AE; Levine MM; Lepetic A; François N; Yarzabal JP; Schuerman L
    Hum Vaccin; 2011 May; 7(5):511-22. PubMed ID: 21441782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: Booster dose and 2-dose catch-up regimens in the second year of life.
    Odusanya OO; Kuyinu YA; Kehinde OA; Shafi F; François N; Yarzabal JP; Dobbelaere K; Rüggeberg JU; Borys D; Schuerman L
    Hum Vaccin Immunother; 2014; 10(3):757-66. PubMed ID: 24356787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.